Literature DB >> 25549571

Quantitative mass spectrometric immunoassay for the chemokine RANTES and its variants.

Olgica Trenchevska1, Nisha D Sherma2, Paul E Oran2, Peter D Reaven3, Randall W Nelson2, Dobrin Nedelkov2.   

Abstract

The chemokine RANTES plays a key role in inflammation, cell recruitment and T cell activation. RANTES is heterogenic and exists as multiple variants in vivo. Herein we describe the development and characterization of a fully quantitative mass spectrometric immunoassay (MSIA) for analysis of intact RANTES and its proteoforms in human serum and plasma samples. The assay exhibits linearity over a wide concentration range (1.56-200ng/mL), intra- and inter-assay precision with CVs <10%, and good linearity and recovery correlations. The assay was tested in different biological matrices, and it was benchmarked against an existing RANTES ELISA. The new RANTES MSIA was used to analyze RANTES and its proteoforms in a small clinical cohort, revealing the quantitative distribution and frequency of the native and truncated RANTES proteoforms. BIOLOGICAL SIGNIFICANCE: In the last two decades, RANTES has been studied extensively due to its association with numerous clinical conditions, including kidney-related, autoimmune, cardiovascular, viral and metabolic pathologies. Although a single gene product, RANTES is expressed in a range of cells and tissues presenting with different endogenously produced variants and PTMs. The structural variety and population diversity that has been identified for RANTES necessitate developing advanced methodologies that can provide insight into the protein heterogeneity and its function and regulation in disease. In this work we present a simple, efficient and high-throughput mass spectrometric immunoassay (MSIA) method for analysis of RANTES proteoforms. RANTES MSIA can detect and analyze RANTES proteoforms and provide an insight into the endogenous protein modifications. Published by Elsevier B.V.

Entities:  

Keywords:  Chemokine; Mass spectrometric immunoassay; Quantitative analysis; RANTES

Mesh:

Substances:

Year:  2014        PMID: 25549571      PMCID: PMC4356132          DOI: 10.1016/j.jprot.2014.12.011

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  64 in total

1.  Association of chemokine-mediated block to HIV entry with coreceptor internalization.

Authors:  Stephanie M Brandt; Roberto Mariani; Anne U Holland; Thomas J Hope; Nathaniel R Landau
Journal:  J Biol Chem       Date:  2002-01-08       Impact factor: 5.157

2.  Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma.

Authors:  Eric Kuhn; Jeffrey R Whiteaker; D R Mani; Angela M Jackson; Lei Zhao; Matthew E Pope; Derek Smith; Keith D Rivera; N Leigh Anderson; Steven J Skates; Terry W Pearson; Amanda G Paulovich; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2011-12-22       Impact factor: 5.911

Review 3.  Platelets as immune cells: bridging inflammation and cardiovascular disease.

Authors:  Philipp von Hundelshausen; Christian Weber
Journal:  Circ Res       Date:  2007-01-05       Impact factor: 17.367

Review 4.  Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.

Authors:  Carol E Parker; Christoph H Borchers
Journal:  Mol Oncol       Date:  2014-03-20       Impact factor: 6.603

5.  N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant.

Authors:  Jean K Lim; Wuyuan Lu; Oliver Hartley; Anthony L DeVico
Journal:  J Leukoc Biol       Date:  2006-09-08       Impact factor: 4.962

6.  Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus.

Authors:  L C W Lit; C K Wong; L S Tam; E K M Li; C W K Lam
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

7.  Mass spectrometric immunoassay for quantitative determination of protein biomarker isoforms.

Authors:  Olgica Trenchevska; Elena Kamcheva; Dobrin Nedelkov
Journal:  J Proteome Res       Date:  2010-09-23       Impact factor: 4.466

8.  Chemokine expression during the development and resolution of a pulmonary leukocyte response to influenza A virus infection in mice.

Authors:  Mark D Wareing; Ashley B Lyon; Bao Lu; Craig Gerard; Sally R Sarawar
Journal:  J Leukoc Biol       Date:  2004-07-07       Impact factor: 4.962

9.  Mass spectrometric immunoassay.

Authors:  R W Nelson; J R Krone; A L Bieber; P Williams
Journal:  Anal Chem       Date:  1995-04-01       Impact factor: 6.986

10.  Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach.

Authors:  Steven A Carr; Susan E Abbatiello; Bradley L Ackermann; Christoph Borchers; Bruno Domon; Eric W Deutsch; Russell P Grant; Andrew N Hoofnagle; Ruth Hüttenhain; John M Koomen; Daniel C Liebler; Tao Liu; Brendan MacLean; D R Mani; Elizabeth Mansfield; Hendrik Neubert; Amanda G Paulovich; Lukas Reiter; Olga Vitek; Ruedi Aebersold; Leigh Anderson; Robert Bethem; Josip Blonder; Emily Boja; Julianne Botelho; Michael Boyne; Ralph A Bradshaw; Alma L Burlingame; Daniel Chan; Hasmik Keshishian; Eric Kuhn; Christopher Kinsinger; Jerry S H Lee; Sang-Won Lee; Robert Moritz; Juan Oses-Prieto; Nader Rifai; James Ritchie; Henry Rodriguez; Pothur R Srinivas; R Reid Townsend; Jennifer Van Eyk; Gordon Whiteley; Arun Wiita; Susan Weintraub
Journal:  Mol Cell Proteomics       Date:  2014-01-17       Impact factor: 5.911

View more
  7 in total

Review 1.  Mass spectrometric immunoassays for discovery, screening and quantification of clinically relevant proteoforms.

Authors:  Olgica Trenchevska; Randall W Nelson; Dobrin Nedelkov
Journal:  Bioanalysis       Date:  2016-07-11       Impact factor: 2.681

2.  Development of quantitative mass spectrometric immunoassay for serum amyloid A.

Authors:  Olgica Trenchevska; Hussein N Yassine; Chad R Borges; Randall W Nelson; Dobrin Nedelkov
Journal:  Biomarkers       Date:  2016-07-22       Impact factor: 2.658

Review 3.  Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.

Authors:  Olgica Trenchevska; Randall W Nelson; Dobrin Nedelkov
Journal:  Proteomes       Date:  2016-03-17

Review 4.  Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.

Authors:  Dobrin Nedelkov
Journal:  Proteomes       Date:  2017-10-15

5.  Assuring Consistent Performance of an Insulin-Like Growth Factor 1 MALDImmunoassay by Monitoring Measurement Quality Indicators.

Authors:  Frank Klont; Nick H T Ten Hacken; Péter Horvatovich; Stephan J L Bakker; Rainer Bischoff
Journal:  Anal Chem       Date:  2017-05-10       Impact factor: 6.986

6.  The Human Proteoform Atlas: a FAIR community resource for experimentally derived proteoforms.

Authors:  Michael A R Hollas; Matthew T Robey; Ryan T Fellers; Richard D LeDuc; Paul M Thomas; Neil L Kelleher
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

Review 7.  Immunoaffinity Capillary Electrophoresis in the Era of Proteoforms, Liquid Biopsy and Preventive Medicine: A Potential Impact in the Diagnosis and Monitoring of Disease Progression.

Authors:  Norberto A Guzman; Daniel E Guzman
Journal:  Biomolecules       Date:  2021-10-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.